Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive surprises than negative ones.

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Maybe you stock up on ice cream after a difficult day at work or reach for chocolate after a disagreement with your partner.

The Microdose GLP-1Rx Program will offer low-dose GLP-1 prescriptions combined with behavioral coaching, clinical monitoring and medication management.

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...

In its updated report, Hims & Hers Health, Inc. (NYSE:HIMS) said revenues increased by 73 percent to $544.8 million from $315 ...

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect ...

US stocks end lower after data show higher prices and lower employment. Investors also weigh earnings and Trump tariff threats.

Ten stocks mirrored a lackluster performance in the broader market on Tuesday, posting hefty double-digit losses primarily due to disappointing earnings performance and a lower growth outlook for the ...

Palantir rose after earnings blew past Wall Street estimates, while shares of Vertex Pharmaceuticals and Hims & Hers ...